Related Experiment Video
Updated: Feb 28, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor
Erica F Andersen1,2, Christian N Paxton2, Dennis P O'Malley3,4
1Department of Pathology, University of Utah, Salt Lake City, UT, USA.
Abstract:
Follicular dendritic cell sarcoma is a rare malignant neoplasm of dendritic cell origin that is currently poorly characterized by genetic studies. To investigate whether recurrent genomic alterations may underlie the biology of follicular dendritic cell sarcoma and to identify potential contributory regions and genes, molecular inversion probe array analysis was performed on 14 independent formalin-fixed, paraffin-embedded samples. Abnormal genomic profiles were observed in 11 out of 14 (79%) cases. The majority showed extensive genomic complexity that was predominantly represented by hemizygous losses affecting multiple chromosomes. Alterations of chromosomal regions 1p (55%), 2p (55%), 3p (82%), 3q (45%), 6q (55%), 7q (73%), 8p (45%), 9p (64%), 11q (64%), 13q (91%), 14q (82%), 15q (64%), 17p (55%), 18q (64%), and 22q (55%) were recurrent across the 11 samples showing abnormal genomic profiles. Many recurrent genomic alterations in follicular dendritic cell sarcoma overlap deletions that are frequently observed across human cancers, suggesting selection, or an active role for these alterations in follicular dendritic cell sarcoma pathogenesis. In support of a tumor suppressor-driven biology, homozygous deletions involving tumor suppressor genes CDKN2A, RB1, BIRC3, and CYLD were also observed. Neither recurrent gains nor amplifications were observed. This genomic characterization provides new information regarding follicular dendritic cell sarcoma biology that may improve understanding about the underlying pathophysiology, provide better prognostication, and identify potential therapeutic markers for this rare disease.
Insights
This study reveals frequent genomic alterations in follicular dendritic cell sarcoma (FDCS), primarily deletions, suggesting a tumor suppressor role in its development. These findings may aid in understanding FDCS and identifying therapeutic targets.
Area of Science:
- Oncology
- Genetics
- Genomics
Background:
- Follicular dendritic cell sarcoma (FDCS) is a rare cancer.
- Its genetic underpinnings are poorly understood.
- Genomic alterations may drive FDCS development.
Purpose of the Study:
- To investigate recurrent genomic alterations in FDCS.
- To identify potential driver genes and regions in FDCS pathogenesis.
- To characterize the genetic landscape of this rare sarcoma.
Main Methods:
- Molecular inversion probe array analysis was performed.
- 14 formalin-fixed, paraffin-embedded FDCS samples were analyzed.
- Genomic profiles were assessed for alterations.
Main Results:
- Abnormal genomic profiles were found in 79% of cases.
- Recurrent hemizygous losses were common across multiple chromosomes.
- Homozygous deletions of tumor suppressor genes (e.g., CDKN2A, RB1) were observed.
Conclusions:
- Genomic complexity and deletions are hallmarks of FDCS.
- Findings suggest a tumor suppressor-driven biology in FDCS.
- This genomic characterization may improve prognostication and identify therapeutic markers.
